Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sparsentan - Retrophin

Drug Profile

Sparsentan - Retrophin

Alternative Names: DARA; PS-433540; RE-021

Latest Information Update: 16 Mar 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Retrophin
  • Class Antihypertensives; Isoxazoles; Nerve growth factors; Small molecules; Spiro compounds; Sulfonamides; Urologics
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Focal segmental glomerulosclerosis; IgA nephropathy
  • Discontinued Hypertension

Most Recent Events

  • 10 Mar 2020 Ligand Pharmaceuticals anticipates launch of sparsentan by the end of 2022
  • 09 Mar 2020 Retrophin announces intention to submit Conditional Marketing Authorization (CMA) for Focal segmental glomerulosclerosis in EU
  • 24 Feb 2020 Retrophin announces intention to submit NDA to the US FDA for Focal segmental glomerulosclerosis
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top